Cellaïon is a biotechnology company based in Mont-St-Guibert, active in the field of cell therapy, an area of excellence in the life sciences industry in Wallonia. Its flagship product HepaStem®, in advanced clinical development, targets severe liver diseases, and in particular Acute on Chronic Liver Failure (ACLF). ACLF is an acute hepatic failure leading secondarily to multi-system failure (i.e., other organs such as kidneys, heart, brain, lungs).
Mortality exceeds 50% in the short term. HepaStem® brings hope to counter this hyper-inflammatory condition and to significantly improve the survival of these patients. There is currently no therapeutic alternative, and emergency liver transplantation remains largely inaccessible for these patients.
See website![logo_cellaion_2_couleurs_png_1024x496_717x348.png](/assets/h90-q90-p1/ef53583a/logo_cellaion_2_couleurs_png_1024x496_717x348.png)
![](/themes/TruffleTheme/static/img/fluid-bg/fluid-bg_2x_p4u3tv_c_scale,w_2880.jpg)
Synoptical view
- First investment date
- 2022
![main_labo_1024x689_549x369.png](/assets/f1413x672-q85-p1/985468ac/main_labo_1024x689_549x369.png)